Evolus (EOLS) EBIT (QoQ) (2017 - 2026)
Evolus (EOLS) EBIT (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Evolus | 549.85 Mn | 504.68 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.66% |
| Mar 31, 2026 | -262.27% |
| Dec 31, 2025 | 136.70% |
| Sep 30, 2025 | -12.63% |
| Jun 30, 2025 | 32.70% |
| Mar 31, 2025 | -555.66% |
| Dec 31, 2024 | 85.04% |
| Sep 30, 2024 | -100.90% |
| Jun 30, 2024 | 13.67% |
| Mar 31, 2024 | -3.32% |
| Dec 31, 2023 | 35.75% |
| Sep 30, 2023 | 11.10% |
| Jun 30, 2023 | -25.56% |
| Mar 31, 2023 | -13.19% |
| Dec 31, 2022 | 40.57% |
| Sep 30, 2022 | 16.17% |
| Jun 30, 2022 | -38.19% |
| Mar 31, 2022 | 14.31% |
| Dec 31, 2021 | 5.66% |
| Sep 30, 2021 | -24.96% |